Sep 25, 2025 (PRISM News via COMTEX) --
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies, has announced the pricing of an underwritten public offering of 31,250,000 shares of its common stock at $3.20 per share. The offering is expected to generate gross proceeds of $100 million for the company, prior to deducting underwriting discounts, commissions, and other offering expenses. The transaction is anticipated to close on or around September 26, 2025, subject to customary closing conditions.
In addition to the primary offering, PepGen has granted underwriters a 30-day option to purchase up to 4,687,500 additional shares at the public offering price, less underwriting discounts.
PepGen plans to allocate the net proceeds from this offering to support its ongoing research and clinical development programs. This includes funding for its FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, which are part of its efforts to develop transformative treatments for severe neuromuscular and neurological diseases. Remaining funds will be used for working capital and other general corporate purposes.
Leerink Partners and Stifel are serving as joint bookrunning managers for the offering. The securities are being offered under a registration statement on Form S-3, which was filed with and declared effective by the Securities and Exchange Commission (SEC) on July 8, 2024. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and made available on its website at www.sec.gov.
For additional information or to obtain copies of the final prospectus supplement and accompanying prospectus, interested parties can contact:
Leerink Partners LLC
Syndicate Department
53 State Street, 40th Floor, Boston, MA 02109
Phone: (800) 808-7525 ext. 6105
Email: syndicate@leerink.com
Stifel, Nicolaus & Company, Incorporated
Attention: Syndicate
One Montgomery Street, Suite 3700, San Francisco, CA 94104
Phone: (415) 364â?2720
Email: syndprospectus@stifel.com
This announcement does not constitute an offer to sell or a solicitation to buy these securities in any jurisdiction where such an offer or sale would be unlawful prior to registration or qualification under applicable securities laws.
About PepGen Inc.
PepGen Inc. is a clinical-stage biotechnology company dedicated to advancing oligonucleotide therapies to address severe neuromuscular and neurological diseases. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform is the result of over a decade of research and development. By leveraging cell-penetrating peptides, the EDO platform enhances the uptake and activity of conjugated oligonucleotide therapeutics, enabling the development of treatments that target the root causes of serious diseases. PepGen's innovative approach has led to a robust pipeline of therapeutic candidates aimed at transforming patient outcomes in areas of significant unmet medical need.
For more information please visit www.pepgen.com
The post PepGen Inc. Announces $100 Million Public Offering to Advance Clinical Development appeared first on PRISM MarketView.
COMTEX_469037002/2927/2025-09-25T08:20:10
